Author

Michael D. Alpert

ORCID 0000-0002-4056-9707Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:protein structure· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

Michael FarzaniD· 2 shared Andi Pan· 1 shared Andrea I. d’AquinoiD· 1 shared Baodan Hu· 1 shared Bryan T. MayeriD· 1 shared Carolyn K. JonsiD· 1 shared Catherine M. KasseiD· 1 shared Changxin DongiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Michael FarzanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Engineering Sustained-Release Broadly Neutralizing Antibody Formulations

Carolyn K. Jons, Catherine M. Kasse, Bryan T. Mayer, Ollivier Hyrien, Samya Sen, Emily L. Meany, Andrea I. d’Aquino, Priya Ganesh, Noah Eckman, Changxin Dong, Jerry Yan, Leslee T. Nguyen, Vanessa M. Doulames, Ye Eun Song, Olivia M. Saouaf, , Eric Andrew Appel

This paper develops a hydrogel depot system to prolong the release of broadly neutralizing antibodies, showing improved pharmacokinetics and reduced immune cell-mediated release through co-formulation with anti-inflammatory agents.

bioRxiv · May 27, 2025 · PreprintBioengineering

In vivo affinity maturation of the HIV-1 Env-binding domain of CD4

Andi Pan, Charles C. Bailey, Tianling Ou, Jinge Xu, Tonia Aristotelous, Xin Liu, Baodan Hu, Gogce Crynen, Nickolas Skamangas, Naomi Bronkema, Mai H. Tran, Huihui Mou, Xia Zhang, Michael D. Alpert, Yiming Yin, , Wenhui He

This study demonstrates that non-antibody protein biologics can undergo affinity maturation in vivo, leading to improved binding affinity and neutralization potency against HIV-1.

bioRxiv · Feb 3, 2024Bioengineering